12 recruiting, 10 not yet recruiting, 1 completed, 1 withdrawn. 10 Phase 2, 6 Phase 1, 3 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow AML (Acute Myeloid Leukemia): new trials by email Literature Review of AML (Acute Myeloid Leukemia) trials Research Report on AML (Acute Myeloid Leukemia)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients CLN-049, Azacitidine, Venetoclax - AML (Acute Myeloid Leukemia) | Phase 1 | Not yet recruiting | Cullinan Therapeutics Inc. | 90 | 2026-10-15 | 2026-07-23 |
| CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults CARCIK CD123/33 infusion - AML (Acute Myeloid Leukemia), BPDCN | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 18 | 2026-10-01 | 2026-10-16 |
| A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML CHM-029 - AML (Acute Myeloid Leukemia) | Phase 1 | Recruiting | Charm Therapeutics | 40 | 2026-09-28 | 2026-10-08 |
| CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML CD64 CAR T Cells - Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | University of Colorado, Denver | 23 | 2026-09-10 | 2026-10-20 |
| HMA-Venetoclax Induction in Newly Diagnosed AML Azacitidine 75 mg/m² SC/IV Days 1-7 + Venetoclax 400 mg orally Days 1-28 (Cycle 1 ramp-up per institutional TLS protocol); 28-day cycles; maximum 2 induction cycles - AML, AML (Acute Myeloid Leukemia) | Phase 2 | Not yet recruiting | Pakistan Blood and Marrow Transplant (PBMT) Group | 60 | 2026-08-01 | 2026-08-05 |
| PRAISE-IR Versus CIBMTR Controls ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia) | Not yet recruiting | Miltenyi Biomedicine GmbH | 51 | 2026-07-31 | 2026-07-28 | |
| Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML Chidamide (Chi)+VAH - AML (Acute Myeloid Leukemia) | Phase 2 | Not yet recruiting | Dongguan People's Hospital | 46 | 2026-06-30 | 2026-06-18 |
| Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS Ivosidenib - AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2026-05-22 | 2026-05-26 |
| VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF - AML (Acute Myeloid Leukemia) | Phase 2 | Recruiting | Beijing 302 Hospital | 48 | 2026-04-15 | 2026-04-07 |
| Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia HSCT with Treg/Tcon adoptive immunotherapy - AML (Acute Myeloid Leukemia) | Phase 2 | Not yet recruiting | Antonio Pierini | 28 | 2026-04-01 | 2026-04-27 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML Arm A (VEN+"2+6"DA), Arm B (DEC3-VEN), Arm C ("3+7"DA) - AML (Acute Myeloid Leukemia) | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | 291 | 2026-04-01 | 2026-07-20 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment Axvitiy Ax3 accelorometer - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Recruiting | University of Oxford | 80 | 2026-02-17 | 2026-04-06 | |
| Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia CAR-T - AML (Acute Myeloid Leukemia) | Phase 1 / Phase 2 | Not yet recruiting | Xuzhou Medical University | 20 | 2026-01-31 | 2026-01-27 |
| Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation - AML, AML (Acute Myeloid Leukemia) | Not applicable | Not yet recruiting | Donghua Zhang | 18 | 2026-01-30 | 2026-01-15 |
| Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML CAR-T - AML (Acute Myeloid Leukemia), CAR-T | Early Phase 1 | Withdrawn | First Affiliated Hospital of Guangxi Medical University | 2026-01-05 | 2026-08-26 | |
| Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation RIC regimen - AML (Acute Myeloid Leukemia), MDS/AML | Phase 2 | Not yet recruiting | University Hospital Tuebingen | 27 | 2026-01-01 | 2025-10-09 |
| Prognostic Impacts of Lipid Profile and BMI in Adult AML AML (Acute Myeloid Leukemia), BMI | Not yet recruiting | Assiut University | 200 | 2025-11-15 | 2025-08-27 | |
| Haplo-Cord HSCT for AML/MDS haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX) - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Not applicable | Recruiting | Fujian Medical University Union Hospital | 82 | 2025-10-20 | 2026-06-10 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Anemia, Refractory, with Excess of Blasts (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Myelodysplastic Syndromes (2) · Cholangiocarcinoma (1) · Glioma (1) · Leukemia (1) · Neoplasms (1) · Recurrence (1)
Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Leukemia, Myeloid (24) · Neoplasms by Histologic Type (24) · Leukemia (23) · Neoplasms (23) · Bone Marrow Diseases (6) · Anemia (5) · Anemia, Refractory (5) · Myelodysplastic Syndromes (4) · Hematologic Neoplasms (2) · Histiocytic Disorders, Malignant (2) · Lymphoma (2) · Neoplasms by Site (2) · Skin Diseases (2)
Azacitidine (4) · venetoclax (4) · Cytarabine (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclophosphamide (1) · Cytochrome P-450 CYP1A2 (1) · Cytochrome P-450 CYP2B6 (1) · Cytochrome P-450 CYP2C19 (1) · Cytochrome P-450 CYP2C8 (1) · Cytochrome P-450 CYP2C9 (1) · Cytochrome P-450 CYP3A (1) · Granulocyte Colony-Stimulating Factor (1) · Idarubicin (1)
Donghua Zhang (2) · Antonio Pierini (1) · Assiut University (1) · Beijing 302 Hospital (1) · Charm Therapeutics (1) · Chongqing Precision Biotech Co., Ltd (1) · Cullinan Therapeutics Inc. (1) · Dongguan People's Hospital (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) · Fujian Medical University Union Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Miltenyi Biomedicine GmbH (1) · Pakistan Blood and Marrow Transplant (PBMT) Group (1)
China (9) · United States (6) · Italy (2) · United Kingdom (2) · Egypt (1) · Germany (1) · Pakistan (1)
Antonio Pierini (1) · Christoph Faul, Dr. (1) · Christoph Rummelt, MD, PhD (1) · Mathew Angelos, MD, PhD (1) · Matthew H Poynton, MBBS (1) · Mohammad S Mohammad, MBBS (1) · Raheel Iftikhar, MBBS,FCPS(Med),FCPS(Cl Haem) (1) · Roger Strair, MD (1) · Yunyan He, PhD (1)
PMID 12424199, PMID 18997171, PMID 25891003, PMID 26450984, PMID 26551633, PMID 27602666, PMID 28436973, PMID 28665419, PMID 29860482, PMID 30372796, PMID 30499168, PMID 31270102, PMID 31431695, PMID 31477550, PMID 31739455, PMID 32247396, PMID 32518291, PMID 33832208, PMID 34455741, PMID 34804017, PMID 39041653, PMID 39919267
2025 (2)